This study is following 75 adults with Gaucher disease type 1 for five years after they received an experimental gene therapy called FLT201. The main goal is to monitor their long-term safety and see how well the treatment's effects last over time. It is a follow-up to an earlier…
Phase: PHASE1, PHASE2 • Sponsor: Spur Therapeutics • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC